Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok) TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...

Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the...

Lung Association to Ignite Movement in Fight Against #1 Cancer Killer of Women CHICAGO, IL--(Marketwired - May 13, 2014) - It's a fact: every five minutes, a woman in the U.S. is told she has lung cancer. That's why the American Lung Association in Greater Chicago is proud...